APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

SGLT2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global SGLT2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174035020330 December 2025198 pages

Choose your research edition.

Industry ResearchSGLT2 Inhibitors Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal SGLT2 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal SGLT2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SGLT2 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal SGLT2 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global SGLT2 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of SGLT2 Inhibitors include Chia Tai-Tianqing Pharmaceutical, Sandoz, Johnson and Johnson, Merck, Kelun Pharmaceutical, Hengrui Medicine, Hansoh Pharmaceutical Group, Boehringer Ingelheim and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global SGLT2 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SGLT2 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SGLT2 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the SGLT2 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

SGLT2 Inhibitors Segment by Company

Chia Tai-Tianqing Pharmaceutical

Sandoz

Johnson and Johnson

Merck

Kelun Pharmaceutical

Hengrui Medicine

Hansoh Pharmaceutical Group

Boehringer Ingelheim

Bristol-Myers Squibb

AstraZeneca

Starpharma

Orifarm

SGLT2 Inhibitors Segment by Type

Dapagliflozin

Canagliflozin

Canagliflozin

Other

SGLT2 Inhibitors Segment by Application

Single Drug

Combination Medication

SGLT2 Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SGLT2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the SGLT2 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of SGLT2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of SGLT2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of SGLT2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. SGLT2 Inhibitors Industry Trends Table 2. SGLT2 Inhibitors Industry Drivers Table 3. SGLT2 Inhibitors Industry Opportunities and Challenges Table 4. SGLT2 Inhibitors Industry Restraints Table 5. Global SGLT2 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global SGLT2 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global SGLT2 Inhibitors Sales by Manufacturers (Pcs) & (2021-2026) Table 8. Global SGLT2 Inhibitors Sales Market Share by Manufacturers Table 9. Global SGLT2 Inhibitors Average Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 10. Global SGLT2 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global SGLT2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global SGLT2 Inhibitors Manufacturers, Product Type & Application Table 13. Global SGLT2 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global SGLT2 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dapagliflozin Table 17. Major Manufacturers of Canagliflozin Table 18. Major Manufacturers of Canagliflozin Table 19. Major Manufacturers of Other Table 20. Global SGLT2 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (Pcs) Table 21. Global SGLT2 Inhibitors Sales by Type (2021-2026) & (Pcs) Table 22. Global SGLT2 Inhibitors Sales by Type (2027-2032) & (Pcs) Table 23. Global SGLT2 Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global SGLT2 Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global SGLT2 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (Pcs) Table 26. Global SGLT2 Inhibitors Revenue by Type (2021-2026) & (Pcs) Table 27. Global SGLT2 Inhibitors Revenue by Type (2027-2032) & (Pcs) Table 28. Global SGLT2 Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global SGLT2 Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Single Drug Table 31. Major Manufacturers of Combination Medication Table 32. Global SGLT2 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (Pcs) Table 33. Global SGLT2 Inhibitors Sales by Application (2021-2026) & (Pcs) Table 34. Global SGLT2 Inhibitors Sales by Application (2027-2032) & (Pcs) Table 35. Global SGLT2 Inhibitors Sales Market Share by Application (2021-2026) Table 36. Global SGLT2 Inhibitors Sales Market Share by Application (2027-2032) Table 37. Global SGLT2 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (Pcs) Table 38. Global SGLT2 Inhibitors Revenue by Application (2021-2026) & (Pcs) Table 39. Global SGLT2 Inhibitors Revenue by Application (2027-2032) & (Pcs) Table 40. Global SGLT2 Inhibitors Revenue Market Share by Application (2021-2026) Table 41. Global SGLT2 Inhibitors Revenue Market Share by Application (2027-2032) Table 42. Global SGLT2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (Pcs) Table 43. Global SGLT2 Inhibitors Sales by Region (2021-2026) & (Pcs) Table 44. Global SGLT2 Inhibitors Sales Market Share by Region (2021-2026) Table 45. Global SGLT2 Inhibitors Sales Forecasted by Region (2027-2032) & (Pcs) Table 46. Global SGLT2 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 47. North America SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Pcs) Table 48. North America SGLT2 Inhibitors Sales by Country (2021-2026) & (Pcs) Table 49. North America SGLT2 Inhibitors Sales by Country (2027-2032) & (Pcs) Table 50. Europe SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Pcs) Table 51. Europe SGLT2 Inhibitors Sales by Country (2021-2026) & (Pcs) Table 52. Europe SGLT2 Inhibitors Sales by Country (2027-2032) & (Pcs) Table 53. Asia Pacific SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Pcs) Table 54. Asia Pacific SGLT2 Inhibitors Sales by Country (2021-2026) & (Pcs) Table 55. Asia Pacific SGLT2 Inhibitors Sales by Country (2027-2032) & (Pcs) Table 56. South America, Middle East and Africa SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Pcs) Table 57. South America, Middle East and Africa SGLT2 Inhibitors Sales by Country (2021-2026) & (Pcs) Table 58. South America, Middle East and Africa SGLT2 Inhibitors Sales by Country (2027-2032) & (Pcs) Table 59. Global SGLT2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global SGLT2 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 61. Global SGLT2 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 62. Global SGLT2 Inhibitors Revenue Market Share by Region (2021-2026) Table 63. Global SGLT2 Inhibitors Revenue Market Share by Region (2027-2032) Table 64. Chia Tai-Tianqing Pharmaceutical Company Information Table 65. Chia Tai-Tianqing Pharmaceutical Business Overview Table 66. Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Product Portfolio Table 68. Chia Tai-Tianqing Pharmaceutical Recent Development Table 69. Sandoz Company Information Table 70. Sandoz Business Overview Table 71. Sandoz SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sandoz SGLT2 Inhibitors Product Portfolio Table 73. Sandoz Recent Development Table 74. Johnson and Johnson Company Information Table 75. Johnson and Johnson Business Overview Table 76. Johnson and Johnson SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson and Johnson SGLT2 Inhibitors Product Portfolio Table 78. Johnson and Johnson Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck SGLT2 Inhibitors Product Portfolio Table 83. Merck Recent Development Table 84. Kelun Pharmaceutical Company Information Table 85. Kelun Pharmaceutical Business Overview Table 86. Kelun Pharmaceutical SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Kelun Pharmaceutical SGLT2 Inhibitors Product Portfolio Table 88. Kelun Pharmaceutical Recent Development Table 89. Hengrui Medicine Company Information Table 90. Hengrui Medicine Business Overview Table 91. Hengrui Medicine SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Hengrui Medicine SGLT2 Inhibitors Product Portfolio Table 93. Hengrui Medicine Recent Development Table 94. Hansoh Pharmaceutical Group Company Information Table 95. Hansoh Pharmaceutical Group Business Overview Table 96. Hansoh Pharmaceutical Group SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Hansoh Pharmaceutical Group SGLT2 Inhibitors Product Portfolio Table 98. Hansoh Pharmaceutical Group Recent Development Table 99. Boehringer Ingelheim Company Information Table 100. Boehringer Ingelheim Business Overview Table 101. Boehringer Ingelheim SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Boehringer Ingelheim SGLT2 Inhibitors Product Portfolio Table 103. Boehringer Ingelheim Recent Development Table 104. Bristol-Myers Squibb Company Information Table 105. Bristol-Myers Squibb Business Overview Table 106. Bristol-Myers Squibb SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Bristol-Myers Squibb SGLT2 Inhibitors Product Portfolio Table 108. Bristol-Myers Squibb Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca SGLT2 Inhibitors Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Starpharma Company Information Table 115. Starpharma Business Overview Table 116. Starpharma SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Starpharma SGLT2 Inhibitors Product Portfolio Table 118. Starpharma Recent Development Table 119. Orifarm Company Information Table 120. Orifarm Business Overview Table 121. Orifarm SGLT2 Inhibitors Sales (Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Orifarm SGLT2 Inhibitors Product Portfolio Table 123. Orifarm Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. SGLT2 Inhibitors Distributors List Table 127. SGLT2 Inhibitors Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. SGLT2 Inhibitors Product Image Figure 2. Global SGLT2 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SGLT2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global SGLT2 Inhibitors Sales (2021-2032) & (Pcs) Figure 5. Global SGLT2 Inhibitors Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 SGLT2 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dapagliflozin Image Figure 9. Canagliflozin Image Figure 10. Canagliflozin Image Figure 11. Other Image Figure 12. Global SGLT2 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (Pcs) Figure 13. Global SGLT2 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global SGLT2 Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global SGLT2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (Pcs) Figure 16. Global SGLT2 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global SGLT2 Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Single Drug Image Figure 19. Combination Medication Image Figure 20. Global SGLT2 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (Pcs) Figure 21. Global SGLT2 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global SGLT2 Inhibitors Sales Market Share by Application (2021-2032) Figure 23. Global SGLT2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (Pcs) Figure 24. Global SGLT2 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global SGLT2 Inhibitors Revenue Market Share by Application (2021-2032) Figure 26. North America SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 27. North America SGLT2 Inhibitors Sales Market Share by Country (2021-2032) Figure 28. U.S. SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 29. Canada SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 30. Mexico SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 31. Europe SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 32. Europe SGLT2 Inhibitors Sales Market Share by Country (2021-2032) Figure 33. Germany SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 34. France SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 35. U.K. SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 36. Italy SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 37. Netherlands SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 38. Asia Pacific SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 39. Asia Pacific SGLT2 Inhibitors Sales Market Share by Country (2021-2032) Figure 40. China SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 41. Japan SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 42. South Korea SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 43. Southeast Asia SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 44. India SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 45. Australia SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 46. South America, Middle East and Africa SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 47. South America, Middle East and Africa SGLT2 Inhibitors Sales Market Share by Country (2021-2032) Figure 48. Brazil SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 49. South Africa SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 50. Saudi Arabia SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 51. Turkey SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 52. Argentina SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 53. UAE SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 54. Egypt SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 55. Chile SGLT2 Inhibitors Sales and Growth Rate (2021-2032) & (Pcs) Figure 56. Global SGLT2 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global SGLT2 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America SGLT2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 59. North America SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe SGLT2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. Europe SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific SGLT2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa SGLT2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. SGLT2 Inhibitors Value Chain Figure 67. Manufacturing Cost Structure Figure 68. SGLT2 Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Dapagliflozin
  • Canagliflozin
  • Canagliflozin
  • Other
Applications
  • Single Drug
  • Combination Medication
Companies covered
  • Chia Tai-Tianqing Pharmaceutical
  • Sandoz
  • Johnson and Johnson
  • Merck
  • Kelun Pharmaceutical
  • Hengrui Medicine
  • Hansoh Pharmaceutical Group
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • AstraZeneca
  • Starpharma
  • Orifarm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global SGLT2 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global SGLT2 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global SGLT2 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global SGLT2 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global SGLT2 Inhibitors Market Dynamics
  1. 2.1 SGLT2 Inhibitors Industry Trends
  2. 2.2 SGLT2 Inhibitors Industry Drivers
  3. 2.3 SGLT2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 SGLT2 Inhibitors Industry Restraints
3 SGLT2 Inhibitors Market by Manufacturers
  1. 3.1 Global SGLT2 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global SGLT2 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global SGLT2 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global SGLT2 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global SGLT2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global SGLT2 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global SGLT2 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global SGLT2 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 SGLT2 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 SGLT2 Inhibitors Tier 1, Tier 2, and Tier 3
4 SGLT2 Inhibitors Market by Type
  1. 4.1 SGLT2 Inhibitors Type Introduction
  2. 4.1.1 Dapagliflozin
  3. 4.1.2 Canagliflozin
  4. 4.1.3 Canagliflozin
  5. 4.1.4 Other
  6. 4.2 Global SGLT2 Inhibitors Sales by Type
  7. 4.2.1 Global SGLT2 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global SGLT2 Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global SGLT2 Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global SGLT2 Inhibitors Revenue by Type
  11. 4.3.1 Global SGLT2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global SGLT2 Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global SGLT2 Inhibitors Revenue Market Share by Type (2021-2032)
5 SGLT2 Inhibitors Market by Application
  1. 5.1 SGLT2 Inhibitors Application Introduction
  2. 5.1.1 Single Drug
  3. 5.1.2 Combination Medication
  4. 5.2 Global SGLT2 Inhibitors Sales by Application
  5. 5.2.1 Global SGLT2 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global SGLT2 Inhibitors Sales by Application (2021-2032)
  7. 5.2.3 Global SGLT2 Inhibitors Sales Market Share by Application (2021-2032)
  8. 5.3 Global SGLT2 Inhibitors Revenue by Application
  9. 5.3.1 Global SGLT2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global SGLT2 Inhibitors Revenue by Application (2021-2032)
  11. 5.3.3 Global SGLT2 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global SGLT2 Inhibitors Sales by Region
  1. 6.1 Global SGLT2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SGLT2 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global SGLT2 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global SGLT2 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America SGLT2 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe SGLT2 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific SGLT2 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa SGLT2 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa SGLT2 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global SGLT2 Inhibitors Revenue by Region
  1. 7.1 Global SGLT2 Inhibitors Revenue by Region
  2. 7.1.1 Global SGLT2 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global SGLT2 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global SGLT2 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global SGLT2 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America SGLT2 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe SGLT2 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific SGLT2 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa SGLT2 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa SGLT2 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai-Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Product Portfolio
  6. 8.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz SGLT2 Inhibitors Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Johnson and Johnson
  14. 8.3.1 Johnson and Johnson Company Information
  15. 8.3.2 Johnson and Johnson Business Overview
  16. 8.3.3 Johnson and Johnson SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson SGLT2 Inhibitors Product Portfolio
  18. 8.3.5 Johnson and Johnson Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck SGLT2 Inhibitors Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Kelun Pharmaceutical
  26. 8.5.1 Kelun Pharmaceutical Company Information
  27. 8.5.2 Kelun Pharmaceutical Business Overview
  28. 8.5.3 Kelun Pharmaceutical SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kelun Pharmaceutical SGLT2 Inhibitors Product Portfolio
  30. 8.5.5 Kelun Pharmaceutical Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine SGLT2 Inhibitors Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
  37. 8.7 Hansoh Pharmaceutical Group
  38. 8.7.1 Hansoh Pharmaceutical Group Company Information
  39. 8.7.2 Hansoh Pharmaceutical Group Business Overview
  40. 8.7.3 Hansoh Pharmaceutical Group SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hansoh Pharmaceutical Group SGLT2 Inhibitors Product Portfolio
  42. 8.7.5 Hansoh Pharmaceutical Group Recent Developments
  43. 8.8 Boehringer Ingelheim
  44. 8.8.1 Boehringer Ingelheim Company Information
  45. 8.8.2 Boehringer Ingelheim Business Overview
  46. 8.8.3 Boehringer Ingelheim SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim SGLT2 Inhibitors Product Portfolio
  48. 8.8.5 Boehringer Ingelheim Recent Developments
  49. 8.9 Bristol-Myers Squibb
  50. 8.9.1 Bristol-Myers Squibb Company Information
  51. 8.9.2 Bristol-Myers Squibb Business Overview
  52. 8.9.3 Bristol-Myers Squibb SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb SGLT2 Inhibitors Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca SGLT2 Inhibitors Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Starpharma
  62. 8.11.1 Starpharma Company Information
  63. 8.11.2 Starpharma Business Overview
  64. 8.11.3 Starpharma SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Starpharma SGLT2 Inhibitors Product Portfolio
  66. 8.11.5 Starpharma Recent Developments
  67. 8.12 Orifarm
  68. 8.12.1 Orifarm Company Information
  69. 8.12.2 Orifarm Business Overview
  70. 8.12.3 Orifarm SGLT2 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Orifarm SGLT2 Inhibitors Product Portfolio
  72. 8.12.5 Orifarm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 SGLT2 Inhibitors Value Chain Analysis
  2. 9.1.1 SGLT2 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 SGLT2 Inhibitors Production Mode & Process
  6. 9.2 SGLT2 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 SGLT2 Inhibitors Distributors
  9. 9.2.3 SGLT2 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst